NCT06611670

Brief Summary

Cataract surgery is a widely performed procedure across the world that helps restore vision in many patients suffering from cataracts. Irrigation is an essential component of the surgery. Fluid is constantly circulated to help regulate temperature as heat is generated with ultrasound energy, to minimize tissue trauma, and to create an intraocular pressure (IOP) sufficient to keep the anterior chamber (AC) stable. In parallel, aspiration brings the components of the cataract closer to the surgical instrument. A balance between irrigation and aspiration during surgery is essential to maintain stability in the AC. However, an ideal flow rate, which influences IOP during surgery, is yet to be determined. Most recent studies with Centurion Active Sentry show that there is similar efficiency between higher and lower IOP settings. Traditionally, high-flow rates have been used in advanced cataracts and are believed to make space in the AC. However, they are known to create fluid turbulence and are associated with risks of tissue damage, including cell loss in one of the cornea's layers. High IOP during surgery has also been shown to cause damage to the optic nerve as well as to the retina. Distorting and stretching the AC during phacoemulsification have also been associated with increased pain experienced by the patient. Comfort can be achieved by lowering pressure levels. Low-flow rates have a better safety profile, reduce IOP and pressure fluctuations while offering equal efficiency, including comparable surgical time. Using central corneal thickness (CCT) as an indicator of corneal trauma, it has been shown that patients that have had surgery with low-flow rates present no change in the CCT postoperatively as opposed to patients in the high-flow rates. As less fluid turbulence is created with low-flow rates, there is decreased risk of fragment contact with the cornea's inner surface, thus reducing cell loss. Alcon Laboratories, Inc. developed Active Fluidics which allows to stabilize intraocular pressure and prevent IOP fluctuations as well as IOP surges during surgery. It is now further equipped with the Active Sentry handpiece which is integrated to the surgical instrument and acts as a sensor to pressure variation. It allows rapid feedback to maintain a stable AC. Our research project aims to assess the outcomes following phacoemulsification done with physiological IOP with the help of the Active Sentry handpiece compared to traditional high IOP levels.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
38

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2024

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 22, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 25, 2024

Completed
6 days until next milestone

Study Start

First participant enrolled

October 1, 2024

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2025

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2025

Completed
Last Updated

September 25, 2024

Status Verified

September 1, 2024

Enrollment Period

4 months

First QC Date

September 22, 2024

Last Update Submit

September 22, 2024

Conditions

Keywords

Active Sentrycataract surgerycataractsHigh intra-ocular pressurecentral corneal thicknessintraocular pressurephacoemulsificationsafety profilephysiological IOP

Outcome Measures

Primary Outcomes (1)

  • Central corneal thickness at 1 day postoperatively

    Using central corneal thickness (CCT) as an indicator of corneal trauma, it has been shown that patients that have had surgery with low-flow rates present no change in the CCT postoperatively. CCT will be measured using a pachymetry (Normal CCT range 540µm ± 50).

    1 day postoperatively

Secondary Outcomes (5)

  • Volume of balanced salt solution used during surgery

    During surgery

  • Total ultrasound time and total aspiration time

    During surgery

  • Endothelial cell loss (inner surface of the cornea)

    At month 1 and month 3 postoperatively.

  • Central corneal thickness

    1 week, 1 month and 3 months postoperatively

  • Corneal clarity

    Day 1, week 1, month 1 and month 3 postoperatively

Other Outcomes (7)

  • Visual acuity

    Day 1, week 1, month 1, and month 3 postoperatively

  • Low contrast evaluation

    Day 1, week 1, month 1, and month 3 postoperatively

  • Intraocular pressure

    Day 1, week 1, month 1, and month 3 postoperatively

  • +4 more other outcomes

Study Arms (2)

Cataract surgery with Active Sentry

EXPERIMENTAL

Cataract surgery with low IOP values (32mmHg)

Device: Cataract surgery with Active Sentry

High IOP

ACTIVE COMPARATOR

Cataract surgery with high IOP (60mmHg) which is the average pressure at which cataract surgery is being performed currently

Procedure: Traditional cataract surgery

Interventions

Surgical instrument that detects changes in intraocular pressure and allows rapid feedback to stabilize pressure during cataract surgery.

Cataract surgery with Active Sentry

Cataract surgery performed with high intraocular pressures

High IOP

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • No prior ocular surgery including corneal refractive surgery
  • Bilateral visually significant cataract, similar in density (LOCS III grade 2+), undergoing uncomplicated cataract surgery
  • Equal dilated pupil size ≥6mm, no use of pupil expansion devices
  • Axial length 22-26mm, refractive error between -5.00D to +5.00D and cylinder ≤ 3.00D, normal K values \<47.00D
  • Axial eye length cannot vary by more than 0.4 mm between eyes of an individual patient
  • Normal CCT range 540µm ± 50

You may not qualify if:

  • History of corneal disease or dystrophies
  • Media opacification for reasons other than cataract
  • Compromised zonular integrity or stability.
  • Retinal and retinal vascular pathologies, age-related macular degeneration
  • Glaucoma
  • Patients with uncontrolled systematic diseases, including hypertension, diabetes, systemic cardiovascular diseases, and hematological diseases.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Zhao Y, Li X, Tao A, Wang J, Lu F. Intraocular pressure and calculated diastolic ocular perfusion pressure during three simulated steps of phacoemulsification in vivo. Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2927-31. doi: 10.1167/iovs.08-2996. Epub 2009 Jan 24.

    PMID: 19168897BACKGROUND
  • Vasavada AR, Praveen MR, Vasavada VA, Vasavada VA, Raj SM, Asnani PK, Garg VS. Impact of high and low aspiration parameters on postoperative outcomes of phacoemulsification: randomized clinical trial. J Cataract Refract Surg. 2010 Apr;36(4):588-93. doi: 10.1016/j.jcrs.2009.11.009.

    PMID: 20362850BACKGROUND

MeSH Terms

Conditions

Cataract

Interventions

Cataract Extraction

Condition Hierarchy (Ancestors)

Lens DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Refractive Surgical ProceduresOphthalmologic Surgical ProceduresSurgical Procedures, Operative

Study Officials

  • Samir Jabbour, MD,CM,FRCSC

    Centre hospitalier de l'Université de Montréal (CHUM)

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Samir Jabbour, MD,CM,FRCSC

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Interventional single-masked pair-eye design clinical trial, single-center, single-surgeon. Eyes will be block-randomized as to which surgery they will receive first (high vs low IOP phacoemulsification). 76 eyes of 38 patients will be included in this study. For each patient, one eye will be randomized to receive phacoemulsification with high IOP (Group 1), and the other eye will receive phacoemulsification with physiological IOP (Group 2). This way, each patient will receive both treatments, one for each eye, which will allow us to do paired analyses.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ophthalmologist, Assistant clinical professor

Study Record Dates

First Submitted

September 22, 2024

First Posted

September 25, 2024

Study Start

October 1, 2024

Primary Completion

February 1, 2025

Study Completion

March 1, 2025

Last Updated

September 25, 2024

Record last verified: 2024-09

Data Sharing

IPD Sharing
Will not share